Literature DB >> 6967398

An overview of the current status of levamisole in the treatment of rheumatic diseases.

E C Huskisson, J G Adams.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6967398     DOI: 10.2165/00003495-198020020-00002

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


× No keyword cloud information.
  7 in total

1.  A study of the hematological side effects of levamisole in rheumatoid arthritis with recommendations.

Authors:  H Mielants; E M Veys
Journal:  J Rheumatol Suppl       Date:  1978

2.  Mode of action of levamisole.

Authors:  G Goldstein
Journal:  J Rheumatol Suppl       Date:  1978

3.  Immunostimulant therapy with levamisole for rheumatoid arthritis.

Authors:  E C Huskisson; J Scott; H W Balme; P A Dieppe; J Trapnell; D A Willoughby
Journal:  Lancet       Date:  1976-02-21       Impact factor: 79.321

Review 4.  Adverse reactions to levamisole.

Authors:  J Symoens; E Veys; M Mielants; R Pinals
Journal:  Cancer Treat Rep       Date:  1978-11

5.  A multicentre randomized double-blind study comparing two dosages of levamisole in rheumatoid arthritis.

Authors: 
Journal:  J Rheumatol Suppl       Date:  1978

6.  Levamisole in rheumatoid arthritis. A randomised double-blind study comparing two dosage regimens of levamisole with placebo. Multicentre study group.

Authors: 
Journal:  Lancet       Date:  1978-11-11       Impact factor: 79.321

7.  Immunokinetics of a single dose of levamisole.

Authors:  T Di Perri; A Auteri; F Laghi Pasini
Journal:  J Immunopharmacol       Date:  1979
  7 in total
  2 in total

Review 1.  Treatment of severe rheumatoid arthritis.

Authors:  V Wright
Journal:  Br Med J (Clin Res Ed)       Date:  1986-02-15

Review 2.  Levamisole/fluorouracil. A review of their pharmacology and adjuvant therapeutic use in colorectal cancer.

Authors:  P Chrisp; D McTavish
Journal:  Drugs Aging       Date:  1991 Jul-Aug       Impact factor: 3.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.